logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Metabasis Therapeutics, Inc.


USPTO Granted Patents = 63



Forward Citations = 1,164

Loading Chart...
Loading Chart...

107 inventors (with patents filed for the assignee):

goldMedal Mark D Erion (42 out of 61 patents)

silverMedal K Raja Reddy (31 out of 32 patents)

bronzeMedal Qun Dang (24 out of 51 patents)

4.  Serge H Boyer (24 out of 44 patents)

5.  Scott J Hecker (14 out of 60 patents)

6.  Zhili Sun (12 out of 12 patents)

7.  Brett C Bookser (11 out of 21 patents)

8.  Bheemarao G Ugarkar (10 out of 17 patents)

9.  Venkat Reddy Mali (9 out of 59 patents)

10.  Jorge E Gomez-Galeno (9 out of 9 patents)

11.  Matthew P Grote (9 out of 9 patents)

12.  Thanh Huu Nguyen (9 out of 9 patents)

13.  Robert Huerta Lemus (9 out of 18 patents)

14.  Haiqing Li (9 out of 11 patents)

15.  Srinivas Rao Kasibhatla (9 out of 24 patents)


Core Competencies:
Thyroid Beta-Agonists
Glucagon Antagonists
Thyromimetics
Diacylglycerol O-Acyltransferase Inhibitors
Glucokinase Activators
Phosphorus-Containing Prodrugs
Cyclic Benzimidazole Derivatives
Nucleoside Prodrugs
FBPase Inhibitors
Tyrosine Phosphatase Inhibitors
Fructose-1,6-Bisphosphatase Inhibitors
Liver Specific Drug Delivery

63 patents:

1. 12440502 - Use of thyroid beta-agonists (2025-10-14),
2. 11951114 - Use of thyroid beta-agonists (2024-04-09),
3. 11352321 - Glucagon antagonists (2022-06-07),
4. 11351183 - Use of thyroid beta-agonists (2022-06-07),
5. 10925885 - Thyromimetics for the treatment of fatty liver diseases (2021-02-23),
6. 10807946 - Antagonists of the glucagon receptor (2020-10-20),
7. 10709718 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2020-07-14),
8. 10420781 - Thyroid hormone receptor agonist and use thereof (2019-09-24),
9. 10239829 - Antagonists of the glucagon receptor (2019-03-26),
10. 10221130 - Glucagon antagonists (2019-03-05),
11. 10174062 - Activators of glucokinase (2019-01-08),
12. 10130643 - Thyromimetics for the treatment of fatty liver diseases (2018-11-20),
13. 10034891 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2018-07-31),
14. 9783494 - Glucagon antagonists (2017-10-10),
15. 9701626 - Antagonists of the glucagon receptor (2017-07-11),
Metabasis Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel drugs to treat metabolic and liver diseases. With a strong expertise in drug discovery, Metabasis focuses on the development of drugs that target liver diseases such as non-alcoholic steatohepatitis (NASH) and liver cancer. Through its innovative approaches, Metabasis aims to improve the lives of patients suffering from serious liver conditions.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

63 Patents

#99 in San Diego, CA

#1,304 in California

#5,526 in US

#11,184 in the World

...
San Diego, CA, United States of America

Metabasis Therapeutics, Inc.

Forward Citations = 1,164

107 inventors:

goldMedal Mark D Erion (42 out of 61 patents)

silverMedal K Raja Reddy (31 out of 32 patents)

bronzeMedal Qun Dang (24 out of 51 patents)

4.  Serge H Boyer (24 out of 44 patents)

5.  Scott J Hecker (14 out of 60 patents)

Please report any incorrect information to support@idiyas.com
Loading…